Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 known ✓ | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 known ✓ | O43526 | 1/20 | 0.43 |
| ▸ | KCNQ1 known ✓ | P51787 | 1/20 | 0.43 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.45 |
| ▸ | VNN1 | O95497 | 9/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2063413 | 0.98 | TAS1R3 (0.46) | TAS1R3TAS1R1TAS1R2VNN1KCNQ3 | |
| Hydrochloric Acid SCHEMBL15732413 | 0.87 | KIF11 (0.50) | KCNQ3KCNQ2KCNE1KCNQ1KIF11 | |
| SCHEMBL5430185 | 0.83 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2VNN1KCNQ3 | |
| SCHEMBL311832 | 0.82 | TSHR (0.41) | TAS1R3TAS1R1TAS1R2HDAC8 | |
| SCHEMBL2074095 | 0.81 | TAS1R3 (0.49) | TAS1R3TAS1R1TAS1R2VNN1KCNQ3 | |
| SCHEMBL30129534 | 0.81 | PTPN1 (0.56) | TAS1R3TAS1R1TAS1R2VNN1KCNQ3 | |
| SCHEMBL129133 | 0.81 | PTPN1 (0.56) | TAS1R3TAS1R1TAS1R2VNN1KCNQ3 | |
| SCHEMBL5312305 | 0.81 | TAS1R3 (0.49) | TAS1R3TAS1R1TAS1R2VNN1KCNQ3 | |
| Hydrochloric Acid SCHEMBL4372865 | 0.81 | VNN1 (0.53) | TAS1R3TAS1R1TAS1R2VNN1KCNQ3 | |
| Hydrochloric Acid SCHEMBL30301350 | 0.80 | CES2 (0.57) | VNN1KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755965-B1 | NOVEL IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2017-07-26 | — | — | EP | disclosed |
| US-20160000785-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-9145392-B2 | Imidazole amines as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-29 | — | — | US | disclosed |
| US-20140343029-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| EP-2755965-A1 | NOVEL IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2014-07-23 | — | — | EP | disclosed |
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013040059-A1 | NOVEL IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
| US-8334293-B2 | P70 S6 kinase inhibitor and EGFR inhibitor combination therapy | ELI LILLY AND COMPANY (US) | 2012-12-18 | — | — | US | disclosed |
| EP-2358710-B1 | AKT AND P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8148387-B2 | AKT and P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110212977-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110207752-A1 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2355821-A1 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY | Eli Lilly and Company (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2355820-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | Eli Lilly and Company (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010056574-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056575-A1 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2010-05-13 | — | — | US | disclosed |
| EP-2148880-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| WO-2008140947-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212977-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | MTOR, RPS6KA1, RPS6KA4 | KCNQ3 2280/4885KCNQ2 2048/4885KCNQ1 2141/4885 |
| US-20100120801-A1 | AKT AND P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, MTOR | KCNQ3 3024/4885KCNQ2 2386/4885KCNQ1 2504/4885 |
| US-20160000785-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MAP3K11, MAP3K20, MAP3K19 | KCNQ3 2910/4885KCNQ2 2128/4885KCNQ1 1917/4885 |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | KCNQ3 2917/4885KCNQ2 2377/4885KCNQ1 2433/4885 |
| US-20110207752-A1 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY | RPS6KA1, RPS6KA3, RPS6KA4 | KCNQ3 2713/4885KCNQ2 2560/4885KCNQ1 2612/4885 |
| US-20140343029-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MAP3K11, MAP3K20, MAP3K19 | KCNQ3 2910/4885KCNQ2 2128/4885KCNQ1 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.